Cite
HARVARD Citation
Vormoor, B. et al. (2017). A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Pediatric blood & cancer. 64 (6), p. n/a. [Online].